We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.88B
AUM Growth
-$822M
Cap. Flow
-$1.07B
Cap. Flow %
-15.57%
Top 10 Hldgs %
44.23%
Holding
173
New
23
Increased
20
Reduced
28
Closed
33

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$65.2M
2
PRCT icon
Procept Biorobotics
PRCT
+$63.6M
3
FOLD
Amicus Therapeutics
FOLD
+$35.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$31.4M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$93.6M
2
NVRO
NEVRO CORP.
NVRO
+$73.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$60.8M
4
MDT icon
Medtronic
MDT
+$55.9M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.92%
2 Financials 0.85%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRRO icon
126
Korro Bio
KRRO
$145M
$1.57M 0.02%
4,444
– –
RACE icon
127
Ferrari
RACE
$67.8B
$1.3M 0.02%
6,200
– –
MOTS
128
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$1.24M 0.02%
6,002
– –
RKLY.WS
129
DELISTED
Rockley Photonics Holdings Limited Warrants, each warrant exercisable for one ordinary share at an exercise price of $11.50
RKLY.WS
$1.2M 0.02%
+500,000
New +$1.12M
EIGR
130
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$934K 0.01%
4,663
– –
BFLY.WS
131
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$642K 0.01%
233,333
– –
PHVS icon
132
Pharvaris
PHVS
$2.28B
$479K 0.01%
27,000
– –
SLGCW
133
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$380K 0.01%
+110,000
New +$339K
SRZNW icon
134
Surrozen Inc Warrant
SRZNW
$36.6K
$190K ﹤0.01%
+166,666
New +$229K
CMAXW
135
DELISTED
CareMax, Inc. Warrant
CMAXW
$170K ﹤0.01%
60,000
– –
AKYA
136
DELISTED
Akoya BioSciences
AKYA
– –
-300,000
Closed -$5.8M
AMWL icon
137
American Well
AMWL
$180M
– –
-14,500
Closed -$3.65M
ARWR icon
138
Arrowhead Research
ARWR
$12.1B
– –
-315,141
Closed -$26.1M
COLL icon
139
Collegium Pharmaceutical
COLL
$1.18B
– –
-978,277
Closed -$23.1M
CTMX icon
140
CytomX Therapeutics
CTMX
$690M
– –
-1,640,957
Closed -$10.4M
CVRX icon
141
CVRx
CVRX
$131M
– –
-440,000
Closed -$12.3M
EXAS
142
DELISTED
Exact Sciences
EXAS
– –
-233,523
Closed -$29M
FBRX icon
143
Forte Biosciences
FBRX
$1.57B
– –
-27,400
Closed -$23M
MDT icon
144
Medtronic
MDT
$112B
– –
-450,000
Closed -$55.9M
MREO
145
Mereo BioPharma
MREO
$48.9M
– –
-1,696,068
Closed -$5.38M
MRUS
146
DELISTED
Merus
MRUS
– –
-175,000
Closed -$3.69M
PRVA icon
147
Privia Health
PRVA
$3.04B
– –
-135,000
Closed -$5.99M
RAPT
148
PUT
DELISTED
RAPT Therapeutics
RAPT
– –
-5,625
Closed -$83K
RGEN icon
149
Repligen
RGEN
$6.91B
– –
-132,500
Closed -$26.4M
STOK icon
150
Stoke Therapeutics
STOK
$1.84B
– –
-671,978
Closed -$22.6M
3 4 5
6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Perceptive Advisors held 173 positions worth $6.88B, down 11% from $7.71B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $1.07B in Q3 2021, closing 33 positions and reducing 28 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Icosavax, Inc. Common Stock worth $56.9M.

  • Perceptive Advisors's largest Q3 2021 buy was Icosavax, Inc. Common Stock: 1,922,549 shares worth $56.9M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q3 2021, an estimated $35.2M increase.
  • Perceptive Advisors's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $93.6M.
  • Perceptive Advisors fully exited Kadmon Holdings, Inc. in Q3 2021, selling an estimated $60.8M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.88B portfolio in Q3 2021.
  • Perceptive Advisors opened 23 new positions and closed 33 in Q3 2021.
  • Perceptive Advisors's portfolio value fell 11% quarter-over-quarter to $6.88B.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.